Complex inheritance for susceptibility to sudden cardiac death

Raha Pazoki; Michael W. T. Tanck; Arthur A. M. Wilde; Connie R. Bezzina

doi:https://doi.org/10.2174/138161281939131127112906

Complex inheritance for susceptibility to sudden cardiac death

Raha Pazoki, Michael W. T. Tanck, Arthur A. M. Wilde, Connie R. Bezzina

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Sudden cardiac death (SCD) from ventricular fibrillation during myocardial infarction is a leading cause of total and cardiovascular mortality. It has a multifactorial, complex nature and aggregates in families, implicating the involvement of heritable factors in the determination of risk. During the last few years, genome-wide association studies have uncovered common genetic variants modulating risk of SCD. We here review the current insight on genetic determinants of SCD in the community and describe the genome-wide association approaches undertaken thus far in uncovering genetic determinants of SCD risk

Original language	English
Pages (from-to)	6864-6872
Journal	Current pharmaceutical design
Volume	19
Issue number	39
DOIs	https://doi.org/10.2174/138161281939131127112906
Publication status	Published - 2013

Access to Document

https://doi.org/10.2174/138161281939131127112906

Cite this

@article{16cf43f194c44f1790cb52cbd78c679d,

title = "Complex inheritance for susceptibility to sudden cardiac death",

abstract = "Sudden cardiac death (SCD) from ventricular fibrillation during myocardial infarction is a leading cause of total and cardiovascular mortality. It has a multifactorial, complex nature and aggregates in families, implicating the involvement of heritable factors in the determination of risk. During the last few years, genome-wide association studies have uncovered common genetic variants modulating risk of SCD. We here review the current insight on genetic determinants of SCD in the community and describe the genome-wide association approaches undertaken thus far in uncovering genetic determinants of SCD risk",

author = "Raha Pazoki and Tanck, {Michael W. T.} and Wilde, {Arthur A. M.} and Bezzina, {Connie R.}",

year = "2013",

doi = "https://doi.org/10.2174/138161281939131127112906",

language = "English",

volume = "19",

pages = "6864--6872",

journal = "Current pharmaceutical design",

issn = "1381-6128",

publisher = "Bentham Science Publishers B.V.",

number = "39",

}

TY - JOUR

T1 - Complex inheritance for susceptibility to sudden cardiac death

AU - Pazoki, Raha

AU - Tanck, Michael W. T.

AU - Wilde, Arthur A. M.

AU - Bezzina, Connie R.

PY - 2013

Y1 - 2013

N2 - Sudden cardiac death (SCD) from ventricular fibrillation during myocardial infarction is a leading cause of total and cardiovascular mortality. It has a multifactorial, complex nature and aggregates in families, implicating the involvement of heritable factors in the determination of risk. During the last few years, genome-wide association studies have uncovered common genetic variants modulating risk of SCD. We here review the current insight on genetic determinants of SCD in the community and describe the genome-wide association approaches undertaken thus far in uncovering genetic determinants of SCD risk

AB - Sudden cardiac death (SCD) from ventricular fibrillation during myocardial infarction is a leading cause of total and cardiovascular mortality. It has a multifactorial, complex nature and aggregates in families, implicating the involvement of heritable factors in the determination of risk. During the last few years, genome-wide association studies have uncovered common genetic variants modulating risk of SCD. We here review the current insight on genetic determinants of SCD in the community and describe the genome-wide association approaches undertaken thus far in uncovering genetic determinants of SCD risk

U2 - https://doi.org/10.2174/138161281939131127112906

DO - https://doi.org/10.2174/138161281939131127112906

M3 - Article

C2 - 23590159

SN - 1381-6128

VL - 19

SP - 6864

EP - 6872

JO - Current pharmaceutical design

JF - Current pharmaceutical design

IS - 39

ER -